• Profile

Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era

International Journal of Cancer Nov 12, 2019

Hellesnes R, Kvammen O, Myklebust TA, et al. - Researchers analyzed testicular cancer survivors (TCS) treated in the cisplatin era, to determine second cancer (SC) risk in these individuals in this population-based analysis utilizing complete information on total treatment burden. A total of 5,625 1-year TCS were analyzed. Increased SC risk was observed following surgery only, with site-specific elevated risks of thyroid cancer and melanoma. The risks for cancers of the small intestine, bladder, kidney and lung were found to be increased by 2.0- to 3.7-fold following chemotherapy (CT). Following ≥ 2 cycles of cisplatin-based CT, they observed a 1.6- to 2.1-fold rise in the risk of SC. The risks for cancers of the stomach, small intestine, liver, pancreas, lung, kidney and bladder were found to be increased by 1.5- to 4.4-fold in relation to radiotherapy (RT). Increased risks for hematological malignancies were observed following combined CT and RT. Overall, an increased risk of developing SC was evident in TCS treated in the cisplatin era, especially following treatment with cisplatin-based CT and/or RT.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen